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Reconstruction of bone defects with the use of biomaterials based on hydroxyapatite (HAp) has been a popular 
approach in medicine and dentistry. Most often the process of new bone formation is analyzed with the focus only on the 
region of the reconstructed defect. The effects of the therapy on distant organs have been rarely reported in literature, 
especially not in synergy with the exposure to other bioactive chemicals. In this study, reconstruction of the mandibular 
bone in vivo using poly-lactide-co-glycolide-coated HAp (HAp/PLGA) nanoparticles was monitored with a simultaneous 
histopathological analysis of distant organs, specifically kidney and liver parenchyma. Heavy metals are among the most 
prominent environmental pollutants and have a high affinity for the crystal lattice of HAp, where they get incorporated by 
replacing calcium ions. Lead (Pb) and cadmium (Cd) are two such metals that can be found in food, water and air, but are 
most commonly present in cigarette smoke, the frequent contaminant of hospital settings in the developing world. The 
influence of their presence in the repaired bone on the content of calcium (Ca) in the reconstructed bone defect was 
analyzed, along with the histopathological changes in liver and kidneys. A study performed on 24 female Wistar rats 
demonstrated that the reconstruction of mandibular bone defects using HAp/PLGA particles induced an increase in the 
content of Ca in the newly created bone without causing any pathological changes to the liver and the kidneys. The 
presence of Pb and Cd in the defects reconstructed with HAp/PLGA nanoparticles impeded the regenerative process and 
led to a severe and irreversible damage to the liver and kidney parenchyma.  
Introduction 
 
Calcium phosphates and particularly hydroxyapatite (HAp) as their 
least soluble phase and the phase bearing most structural 
resemblance to biogenic apatite have been widely used in 
reconstructive medicine as materials for the reconstruction of 
damaged or innately defective bones.
1
 HAp has been widely 
regarded as the epitome of a biocompatible, non-immunogenic and 
nontoxic biomaterial at all scales: molecular, cellular, organismic.
2
 
In recent years, the repertoire of applications for HAp-based 
biomaterials has expanded and they have found an application 
niche in preventive medicine as molecular imaging agents, but are 
also used in hyperthermia, photodynamic and radiation therapies.
3
 
Hybrid systems based on HAp and biocompatible and bioresorbable 
polymers have been particularly useful in terms of enabling this 
expansion of the scope of applications for HAp-based biomaterials 
in reconstructive bone tissue surgery and other fields of 
bioengineering.
4,5
 A particularly prospective complement to HAp in 
these hybrid systems has been poly-lactide-co-glycolide (PLGA), a 
biocompatible polymer approved by the Food and Drug 
Administration (FDA) for use in medical devices.
6
  
In a biological environment, degradation of HAp particles is 
enzymatically controlled and mediated by cells.
7
 Phagocytosis of 
HAp is carried out by osteoclasts and macrophages and ultimately 
results in its disintegration to elementary ionic units, namely the 
ions of Ca, phosphate and hydroxyl, which are either excreted or 
used in different metabolic cycles. Monomeric units of lactic and 
glycolic acids as the degradation products of PLGA are more 
structurally complex, but still biocompatible and nontoxic except in 
rare circumstances
8-10
, and are eliminated from the body through 
normal metabolic pathways, such as the tri-carboxylic acid cycle.
6,11
 
Because bioresorbable bone replacement materials, including 
HAp/PLGA, degrade to make way for new bone growth, the focus of 
a thorough biocompatibility analysis must be not only on bone 
regeneration alone, but also on the organs potentially affected by 
these degradation products. At the same time, by the intake of 
food, water and air, there is always a finite possibility of introducing 
small amounts of toxic elements that could potentially affect not 
only the defect reconstruction process, but also the whole 
organism. Heavy metals are among the biggest environmental 
pollutants, and contamination with them can be very harmful 
because of no possibility for biodegradation and because of their 
cumulative toxic effects. Cadmium (Cd) can often appear as a food 
and milk contaminant
12,13
, while lead (Pb) may be present in 
drinking water, especially in aged water supply networks.
14,15 
Both 
Cd and Pb are also common ingredients of tobacco smoke
16-18
, the 
frequent third-hand contaminant in hospital settings
19
, especially in 
the developing world.
20
 Cd are Pb are often found not only in 
tobacco smoke, but also in e-cigarettes, where they form in the 
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interaction between hot vapors and the metallic heating coils.
21
 
Heavy metals, especially Pb, but also Cd, have an affinity for tissues 
that contain inorganic mineral components, such as boney tissues. 
There, they replace calcium in the crystal lattice of HAp, causing the 
loss of bone mass, occurrence of osteoporosis and a change in the 
structural bone integrity, usually in the direction of accelerated 
resorptive metabolic processes in the bone.
22-24
 Retention and 
mobility of these metals in boney tissues modifies the function of 
bone cells, disrupts the metabolism of Ca, thus affecting the 
production of parathyroid hormone, calcitonin, vitamin D as well as 
other hormones that affect Ca metabolism.
25
 Alongside the affinity 
for deposition in bones and for causing osteoporosis, Cd and Pb also 
accumulate in the liver and kidneys.
26,27
 These two metals are also 
cancerous and even a low-level environmental exposure imposes a 
damaging effect on the cardiovascular system.
28
 The metabolic 
dysfunctions caused by them are commonly manifested as the 
occurrence of diabetes.
29-31
 Pb and Cd also induce tubular osteomalacia, 
accompanied by hypophosphatemia, hypocalcaemia and osteoporosis.
30
  
Notwithstanding the importance of in vitro tests, reliable and 
reproducible in vivo assays 
32
 are a necessary step toward the real-
life application of biomaterials in the clinical practice. When it 
comes to HAp, a biomaterial known for its pleiotropy
33
 and ability 
to elicit both cytocompatible and cytotoxic effects
34
, in vitro and in 
vivo assays do not necessarily agree in terms of their outcome
35,36
, 
which even further reinforces the necessity for the use of in vivo 
models to assessing their biomedical potentials. Reparation of large 
bone defects caused by trauma, inflammation or tumor surgery has 
been performed in the clinic using HAp and analyzed in various 
animal models, e.g. dog, sheep, and goat.
37
 The histological analysis 
of bone reparation with HAp in animal models is one of the most 
commonly applied techniques for validation of a successful 
reconstruction process.
38
 In our previous study, we demonstrated a 
successful reconstruction of bone defects with PLGA-coated HAp 
(HAp/PLGA) nanoparticles and analyzed the reconstructed defect by 
histopathological and histomorphometric methods.
39
 Other studies 
were performed using the similar approach and the similar material 
compositions. For example, artificially induced bone defects in 
animals were reconstructed with a hybrid system combining HAp 
and polylactide (PLA), and the osteogenic process in the defect was 
analyzed using infrared spectroscopy.
40
 In another study, the 
possibility of using HAp and PLA-based systems in the orbital wall 
fracture reconstruction was assessed in 70 human subjects, and 
reconstructions were analyzed by means of computerized 
tomography.
41
 Likewise, femoral radiographs of a dog bone defect 
were analyzed before and after the reconstruction of the defect 
with a HAp and PLA composite material.
42
 An HAp/PLA system was 
also used for the internal fixation of bone fractures and the fixation 
performance was analyzed for 7 years by scanning electron 
microscopy (SEM).
43,44
 A histopathological analysis of animal bone 
defects reconstructed with the use of nano-HAp coated with poly-
lactide-co-glycolide (PLGA) and chitosan (Ch) particles was also 
performed in an effort to elucidate the effects of one such 
multipolymeric system on bone regeneration. Common to all these 
analyses was the assessment of the quality of the newly formed 
tissue in the defect only, while marking down the overall morbidity, 




In this study, we attempt to go beyond this approach and focus 
not only on the very defect and its immediate surroundings, but 
also on the effects of reconstruction on two distant organs of 
choice: liver and kidneys. Specifically, we demonstrate the 
reconstruction of the mandibular bone defect in female Wistar rats 
using HAp/PLGA and analyze the contents of calcium (Ca) in the 
reconstructed defect. Ca content is essential for the differentiation 
of progenitor and hematopoietic stem cells into osteogenic and 
osteoclastic phenotypes that form the new bone through mutual 
functional orchestration.
46
 At the same time, histopathological 
methods were used to determine whether the biodegraded 
products of the implant integration process affect organs distant to 
the reconstructed defect, namely kidneys and liver. The influence of 
the presence of Pb and Cd on Ca content in the reconstructed bone 
defects as well as on these two distant organs was analyzed within 
6 - 12 weeks of post-implantation time. The two heavy elements 
were administered simultaneously, given that earlier studies have 
shown that even when elevated concentrations of Pb and Cd alone 




Synthesis of HAp/PLGA particles 
  
Aqueous calcium nitrate (Ca(NO3)2) solution (150 ml; 26.6 wt. %) 
was added to the solution of ammonium phosphate ((NH4)3PO4) (7 
ml H3PO4+165 ml NH4OH+228 ml H2O) at 50 °C over the period of 
60 minutes, while stirring at the rate of 100 rpm. The solution was 
then brought to the boiling point and maintained there for 60 
minutes.
39
 The resulting gel was dried at room temperature in a 
vacuum drier for 72 h, after which the product - HAp particles – was 
obtained. Poly-DL-lactide-co-glycolide (PLGA) (50:50) (Sigma 
Chemical Company, USA) was used as the polymer component. 
HAp/poly-DL-lactide-co-glycolide (HAp/PLGA) particles were 
synthesized by the emulsion procedure using a solvent–non-solvent 
system.
39,48
 The particles of HAp were added to a completely 
dissolved polymeric solution to the concentration of 80 wt.%. The 
suspension was mixed at the velocity of 1000 rpm, at which point 
methanol was added to the mixture. Afterwards, PVA (0.02% in 
water) was added to the suspension (PLGA/PVA = 10/1). After the 
solvent had evaporated in the vacuum drying oven at 20 °C and 1 Pa 
for 6h, the particles were dried at room temperature for 24 h. The 
resulting powder was washed with distilled water three times, 
centrifuged at 1000 rpm and dried again, after which the final 
product was obtained in the form of HAp/PLGA particles with the 
weight ratio of HAp : PLGA of 80 : 20. The encapsulation efficiency 
was 94%. The particles of the HAp/PLGA were sterilized by γ-rays 
(25 kGy) before use.  
 
Characterization of the products 
 
X-Ray diffraction (XRD) was performed on a Philips PW-1050 
diffractometer with Ni-filtered Cu  radiation and the scanning step 
of 0.02°. The particle size distribution (PSD) was measured on 10 
mg/ml of powders dispersed in water using a Mastersizer 2000  
(Malvern Instruments Ltd.) and a HydroS dispersion unit for liquid 
dispersants. Water was selected as the dispersion medium in order 
to reduce the charge screening effect present at the higher ionic 
strength in physiological media and thus minimize particle 
aggregation. Fourier-transform infrared spectroscopy (FT-IR) was 
done on a Nicolet iS10 FT-IR Spectrometer (Thermo Scientific 
Instruments) in the spectral range from 400 to 4000 cm
−1
. 
Morphological analysis was performed using a SUPRA 35 VP Carl 
Zeiss field emission scanning electron microscope (SEM). 
Electrokinetic parameters of the suspensions of synthesized 
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particles were analyzed using a Zeta-Sizer Nano (Malvern 
Instruments Ltd.) in distilled water and pH 6.5. 
 
In vivo experiments 
 
The procedures involving experimental animals were done in 
compliance with the Guidelines for Work with Experimental 
Animals adopted by the Ethical Committee of the Faculty of 
Medicine, University of Niš, Serbia. The experiments were 
performed on white female rats of the Wistar strain aged 6–8 
weeks, of an average weight of 200 g. Animals were raised in the 
laboratory, with a standard diurnal and feeding regimen. Animals 
were divided into two groups: 1) Experimental group (A - 16 
animals); 2) Control group (B - 8 animals). 
In the experimental group of animals, a bone defect 1.4 mm in 
diameter and 1.6 mm in depth in the region between the medial 
line and the foramen mentale on the left side of the mandible was 
induced using a sterile steel borer. HAp/PLGA particles were 
implanted in the mandible defect. The animals belonging to the 
experimental group were further divided into three subgroups: A1 - 
HAp/PLGA particles in the paste form, obtained by mixing 
HAp/PLGA powder with physiological saline; A2 - HAp/PLGA powder 
mixed with a dilute aqueous solution of PbCl2 and CdCl2, the 
concentration of which was adjusted to 5 μg of Pb and 5 μg of Cd 
per gram of the rat’s body weight in total; A3 - HAp/PLGA powder 
mixed with a concentrated solution of Pb and Cd, using the same 
chloride salts, the concentration of which was adjusted to 50 μg of 
Pb and 50 μg Cd per gram of the rat’s body weight in total. 
Compositions of the three sample groups are summed in Table 1.  
Tab. 1 Sample group names and compositions. Units for [Pb] and [Cd] represent the 
amount of the chemical element per the rat’s body weight.  
Sample  HAp/PLGA [Pb] (µg/g) [Cd] (µg/g) 
A1 Yes 0 0 
A2 Yes 5 5 
A3 Yes 50 50 
B No 0 0 
 
In the Control group (B), the regular diurnal and feeding 
regimen was maintained, and these animals received no therapy. 
The animals in all four sample groups (A1, A2, A3, and B) were 
sacrificed 6 and 12 weeks after the implantation. A bone sample 
was obtained from the region between the medial line and the 
foramen mentale on the left side of the mandible, where the 
implantation was performed. Jawbone samples from all four sample 
groups were treated in the mixture of 5ml HNO3 (67%) and 7mL HCl 
(37%) in order to degrade the organic tissue. The mixtures were 
gradually heated until the temperature of 130°C was reached. That 
temperature was maintained during the mineralization period (for 
two hours). After the cooling, 3 x 15 ml of bi-distilled water was 
added to each of the solutions. Solutions were then evaporated 
until the 1-2 ml volume was reached. The solutions with sediments 
were filtered through the Whatman No. 541 filter paper, and the 
filtrates were dissolved in 250 ml of de-ionized water. In these 
solutions, the total concentration of Ca was determined. Ca was 
measured by means of atomic absorption spectrophotometric 
analysis (AAS, Perkin-Elmer M 1100). Bone tissue samples were kept 
in physiological saline, to be subsequently dried until a constant 
mass was reached, grinded and divided into defined aliquots, and 
dissolved in 67% HNO3 at 25-30°C. Then 37% HCl was added and 
steamed until the dry mass was reached, so that the remaining 
nitrogen compounds could be disposed of. By eliminating 
unfavorable effects of nitrates, cations can be translated into 
chloride compounds, which allow for effective detection of 
inorganic components by AAS. For that reason the bone samples 
were dissolved in deionized water until defined aliquots, suitable 
for detection via AAS, were reached. Soft tissue samples (kidney 
and liver) were formalin-fixed and paraffin-embedded for 
histopathological evaluation. Histological sections were stained 
using hematoxylin–eosin (H&E) and periodic acid–Schiff (PAS) 
methods. 
Results and discussion 
Fig. 1 shows the results of the basic physicochemical 
characterization of the synthesized HAp and HAp/PLGA powders. 
The XRD patterns of HAp and HAp/PLGA (Fig. 1a) confirmed a 
poorly crystalline structure of HAp, typical for precipitation under 
ambient conditions and practically any method that circumvents 
high-temperature processing of this compound. Expectedly, no 
peaks corresponding to PLGA were detected in the diffractogram 
because this polymer is amorphous.
49
 The FT-IR spectra of HAp and 
HAp/PLGA are presented in Fig. 1b. They are both dominated by a 
doublet with maxima at 1050 and 1090 cm
−1
, which originate 
from the ν3 antisymmetric stretching mode of the phosphate group. 
Another prominent band originating from a phosphate group 
vibration is the doublet with maxima at somewhat lower 
frequencies of  570 and  600 cm
−1
, arising from the ν4 triply 
degenerated bending mode of the phosphate tetrahedron. The 
absorption maximum at 3560 cm
−1
 originates from the stretch of 
the OH
-
 group, while the relatively intense and sharp band at 1760 
cm
−1
 is attributed to the C=O vibration from PLGA.
48
 The particle 
size distributions in HAp and HAp/PLGA powders are shown in Fig. 
1c. The average mass diameter, d50, corresponding to a value that 
has 50% of the particles smaller than it and 50 % larger than it, 
amounted to 70 nm for HAp, and 82 nm for HAp/PLGA. With d10 = 
47 nm, d50 = 82 nm and d90 = 183 nm, the majority of HAp/PLGA 
particles were nanosized in nature, having less than 100 nm in 
diameter. The measured polydispersion index (PDI) for HAp/PLGA 
particles equalled 0.63. Figure 1d shows the morphology of primary 
particle units within larger agglomerates in dried HAp/PLGA 
powder. The basic spherical nanoparticles of HAp/PLGA joined 
together into bigger agglomerates by adhesive forces.  
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Fig. 1 Results of the physicochemical characterization of HAp and HAp/PLGA 
powder: a) X-ray diffraction pattern, b) FT-IR spectrum, c) particle size 
distribution, and d) an SEM image of dry HAp/PLGA powder.  
Zeta potential (ZP) values at pH 6.5 equalled -7.5 ± 0.5 mV for 
HAp and -22.1 ± 0.9 mV for HAp/PLGA. Generally, ZP values within 
the 0 to ± 15 mV range indicate sols prone to flocculation and 
aggregation, whereas absolute ZP values higher than 15 mV are 
characteristic for stable and aggregation-resistant particles.
50
 
Considering the ZP values for HAp (< 15 mv on the absolute scale) 
and HAp/PLGA (> 15 mV on the absolute scale), it can be concluded 
that the addition of PLGA increases the stability of HAp particles in 
the conditions where surface charge is its main determinant. The 
increased negative charge of the particles resulting from the 
addition of PLGA can be ascribed to the dissociation of carboxylic 
terminal groups and the formation of negatively charged COO
-
 
residues on the particle surface. 
The results presented in Fig. 2 show that the implantation of the 
A1 subgroup of HAp/PLGA nanoparticles, containing neither Pb nor 
Cd, led to an increase in the amount of Ca per weight of the 
reconstructed alveolar bone sample by 6.3 % after 6 weeks and by 
10.7 % after 12 weeks, at which point the increase was statistically 
significant compared to the control B. Ca analysis of bone samples 
from the A2 and A3 subgroups, where the solutions of Pb and Cd 
were mixed in to the implanted paste, showed a reduced bone 
tissue formation compared to both the negative control B and the 
A1 subgroup, which contained neither Pb nor Cd. Compared to the 
control B, the treatment with the diluted solution of Cd and Pb (A2) 
caused a 2.7 % loss of Ca per weight of the reconstructed alveolar 
bone after 6 weeks and a 6.4 % loss after 12 weeks. The Ca loss 
effect was even more significant in animals treated with the A3 
subgroup, containing ten times higher concentration of Pb and Cd 
compared to the A2 subgroup. Specifically, animals in the A3 
subgroup exhibited a 5.1 % decrease in the amount of Ca in the 
alveolar bone after 6 weeks and a 10.8 % decrease after 12 weeks 
compared to the control B, at which point the effect was 
statistically significant compared to A2. These results demonstrate 
that pure HAp/PLGA nanoparticles, uncontaminated with Pb and 
Cd, promoted regeneration of the alveolar bone. This positive 
effect, however, becomes annulled when Pb and Cd are added even 
at comparatively low concentrations to HAp/PLGA 6 weeks after the 
implantation and becomes significantly deleterious 12 weeks after 
the implantation. Higher concentrations of Pb and Cd had an even 
more pronounced effect on reduced bone regeneration with the 
use of HAp/PLGA nanoparticles, in which case the effect was 
statistically significant in comparison to the control already after 6 
weeks. Therefore, the detrimental effect of adding Pb and Cd to 
HAp/PLGA implants was present even at the lowest tested 
concentration of 5 µg x g
-1
 when normalized to the animal body 
weight; it was pronounced both with respect to the bone treated 
with the use HAp/PLGA and the control bone; finally, it increased 
with the concentration of Pb and Cd contaminants and was 
cumulative, becoming more pronounced at longer post-
implantation times. 
 
Fig. 2 Amount of Ca per the weight of the reconstructed alveolar bone of the rats 
6 and 12 weeks after the implantation of the HAp/PLGA nanoparticles. Data 
points are shown as averages and error bars represent standard deviation. 
Statistically significant difference between sample subgroups (p < 0.05) is 
denoted with *. Difference between subgroups that are either not connected 
with an asterisk or connected with n.s. is not statistically significant (p > 0.05).  
The effects of Pb and Cd exhibited directly on the newly grown 
bone are caused by the toxicity of these ions imposed on cells 
populating the bone, but also by the weakening of the bone mineral 
entailed  by the replacement of Ca in apatite crystals by Pb and Cd 
cations having the same valence state as Ca (+2). The ionic radii of Pb 
(133 pm) and Cd (109 pm) differ from the radius of the Ca ion (114 pm) 
and while Pb cation is considerably larger than Ca, Cd is somewhat 
smaller than it. Their substitution for Ca (Fig.3) is thus bound to have 
mutually opposite effects on the lattice of apatite: while Cd will shrink it 
locally, Pb will expand it and the cumulative effect will depend on the 
ratio between the concentrations of the two dopants in the solid phase. 
Because Cd is more similar in size to Ca, which it substitutes for, and Pb is 
significantly larger, it is possible that Cd would accommodate itself more 
efficiently, while Pb may even precipitate as a separate phase, in which 
case lattice contraction could be expected. A recent study demonstrated 
an effect of Pb on altering gene expression in osteoblasts, but also 
showed its close association with the bone mineral, where it localized 
with Ca, but also formed a separate phase.
51
 Concurrent adsorption of Cd 
and Pb on HAp confirmed the formation of a separate precipitate 
containing Pb and retention of the structure and morphology of HAp 
upon the sorption of Cd.
52
 Other adsorption studies on pure HAp have 
shown excellent capture and immobilization of both of these ions 
agreeing 
53-55
 with the earlier established premise that the majority of 
Periodic Table elements could be accommodated stably inside the lattice 
of HAp.
56
 Even though no charge imbalance is introduced to the lattice 
with Ca → Pb/Cd substitution because both Pb and Cd are divalent, like 
Ca, their accommodation will alter the bond angles at the unit cell scale 
and reduce the long-range crystalline symmetry, which is in apatite 
manifested as increased solubility and resorption rate. It should also be 
added that although this ion substitution effect is detrimental to 
the mechanical properties of apatite, it may mitigate some of the 
adverse effect Pb and Cd impose on cells and soft tissues by 
sequestering these toxic ions. Co-administrations of nano-HAp and 
Cd/Pb, for example, has been capable of mitigating the toxic effects 
of the latter ions.
57-59
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Fig. 3 One smaller Cd2+ ion and one larger Pb2+ ion substituting for a columnar, 
Ca1 cation each in the crystal structure of HAp. This ionic size difference causes 
distortions in bond angles and lengths, reducing the overall crystallinity and 
promoting bioresorption. The hexagonal center of symmetry is depicted with a 
dashed line. Different ionic elements are represented with different colors: 
columnar, Ca1 calcium in green, hexagonal, Ca2 calcium in yellow, hydroxyl in 
magenta, phosphate in purple, Cd in light blue and Pb in dark blue.  
To inspect whether the observed changes in the amounts of Ca 
per the weight of the alveolar bone, indicative of the quality of the 
regenerated bone, corresponded to the changes in the liver and the 
kidneys, these two remote organs were subjected to a histological 
analysis, the results of which are shown in Figs. 4-7. Kidney (Fig.4a) 
and liver (Fig.4b) parenchyma of the control group, B, showed a 
perfectly normal histological structure, without any pathological 
changes. No changes were detected in the control group for either 
time interval (6 and 12 weeks). In animals subjected to the 
treatment with the A1 sample subgroup, i.e. HAp/PLGA 
nanoparticles without any exposure to Pb or Cd, the kidney tissue 
samples showed a slight stasis (arrows) in the medulla 6 weeks after 
the implantation (Fig. 5a). Stasis was more pronounced (arrow), 
with slightly dilated lumens of glomerular capillaries (arrowhead), 
12 weeks after the procedure (Fig. 5b). Meanwhile, the proximal 
tubule epithelium was intact, with no cylinders in the lumen, and 
the interstitial appeared slightly expanded. The parenchyma of the 
liver showed a slight dilatation of blood vessels (arrow) 6 weeks 
after the implantation of HAp/PLGA nanoparticles from the same 
subgroup A1 (Fig. 5c), whereas after 12 weeks moderate venostasis 
was present (arrows) (Fig. 5d). No other pathological changes were 
observed. The initial signs of stasis without pathological changes are 
expected to have been the result of the experimental conditions in 
which the animals lived. 
 
 
Fig. 4 Control group (B) showing no histopathological changes: a) kidney, b) liver 
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Fig. 5 Histopathological changes in the parenchymatous organs of animals in the 
experimental subgroup A1: a) kidneys after 6 weeks, b) kidneys after 12 weeks, 
c) liver after 6 weeks, d) liver after 12 weeks. (HE x 20) 
In animals subjected to the treatment with the A2 sample 
subgroup, i.e. HAp/PLGA nanoparticles combined with the lower of 
the two tested concentrations of Pb and Cd, the kidneys, apart from 
stasis, displayed clear signs of degeneration in the tubular 
epithelium, such as scattered desquamation of epithelial cells into 
the lumen (arrows), six weeks after the implantation (Fig. 6a). 
Changes were more prominent 12 weeks after the procedure, at 
which point the examined kidney tissue showed a massive dilatation of capillary 
lumens (arrows), with the extreme narrowing of capsular spaces (arrowheads) 
(Fig. 6b). Epithelial desquamation in the lumen was also noticed, along with the 
slight dilatation of the interstitial blood vessels. The described changes were 
consistent with the stasis in the kidney parenchyma. Apart from the pronounced 
stasis, clear signs of tubular degeneration could be seen and the lumens of both 
small and large blood vessels were dilated. Six weeks after the implantation of 
HAp/PLGA nanoparticles mixed with the dilute solution of Pb and Cd into the 
alveolar bone of the rats, the liver tissue also exhibited signs of stasis, 
alongside the destruction of liver plates as well as the vacuolar 
degeneration of hepatocytes (arrows) and the blood vessel dilatation  
(arrowheads) (Fig. 6c). Dilatation of the blood vessels (arrowheads) and 
changes induced by stasis were more pronounced after 12 weeks and 
accompanied with the degradation of the liver plates and the vacuolar 






Fig. 6 Histopathological changes in the parenchymatous organs of animals in the 
experimental subgroup A2: a) kidneys after 6 weeks, b) kidneys  after 12 weeks, 
c) liver after 6 weeks, d) liver after 12 weeks. (HE x 20) 
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Fig. 7 Histopathological changes in the parenchymatous organs of animals in the 
experimental group A3: a) kidneys after 6 weeks, b) kidneys after 12 weeks, c) 
liver after 6 weeks, d) liver after 12 weeks. (HE x 20) 
Six weeks after the implantation of A3 sample subgroup, i.e. 
HAp/PLGA nanoparticles combined with the higher of the two 
tested concentrations of Pb and Cd, into the alveolar bone of the 
rat, clear changes in the parenchyma of the kidneys were observed. 
Specifically, capsular spaces narrowed (arrowheads) and glomerular 
capillaries showed signs of dilatation. Larger arteries and veins were 
extremely dilated and filled with erythrocytes (arrow) (Fig. 7a). 
Twelve weeks after the intervention, the present glomeruli showed 
major changes caused by stasis, such as the dilatation of capillary 
lumens filled with erythrocytes (arrows) and thrombosis in some 
capillary lumens. The proximal convoluted tubules also displayed 
epithelial necrosis (arrowhead) (Fig. 7b). Six weeks after the 
implantation of HAp/PLGA nanoparticles mixed with the high 
concentration of Cd and Pb, severe degeneration and necrosis of 
hepatocytes (arrows) could be observed in the liver (Fig. 7c). Twelve 
weeks after the intervention, the liver parenchyma exhibited severe 
structural deformation of the hepatic plates, while hepatocytes 
showed signs of hydropic and vacuolar degeneration. The wall of 
vena centralis thickened, without sinusoidal fibrosis or cellular 
infiltration. The pronounced stasis was presents in other parts of 
the parenchyma too (arrows) (Fig. 7d). 
These toxic effects on distal tissue morphologies were detected 
at both the higher and the lower end of the 5 – 50 µg/g of the 
animal body weight range chosen for the concentration of the two 
heavy metals, Pb and Cd. Chronic toxicity for Pb and Cd occurs at 
the blood levels of circa 0.5 μg/ml and 0.05 μg/ml, respectively.
60,61 
Given that the release of these ions from the bone implants will be 
sustained, paralleling the implant resorption, which lasts for longer 
than 12 weeks, the blood concentrations in the animals must have 
been markedly lower than the levels leading to chronic toxicity. 
Also, animal models of acute exposure to Cd and Pb have used the 
orally administered concentrations of 15 and 150 μg/g of the body 
weight in Wistar rats, respectively
62
, which correspond to higher 
heavy metal concentrations than attainable in our model. The fact 
that definite toxic effects were detectable in distal organs following 
the implantation of Pb- and Cd-contaminated HAp/PLGA particles 
shows that even relatively low levels of exposure to these two 
elements combined with surgical bone graft implantation are not to 
be dismissed, given that they can elicit a considerable toxic 
response. The concentrations of heavy metals used in this study 
were, however, circa 500 times higher than those found in an 
average cigarette
63 
and it would be interesting to explore the 
toxicity even at these finer doses resulting from the hypothetical 
exposure of implants to the cigarette smoke.  
Overall, the results of this in vivo study show that Cd and Pb, finding 
way to the bone void and/or the implant filling it, decrease the reparatory 
impact of the filler, in this case HAp/PLGA nanoparticles. Implanted into 
the alveolar bone of experimental animals, these nanoparticles 
significantly improve the bone regeneration rate compared to the 
no-treatment group, but only if the exposure to Pb and Cd is 
avoided. When the treatment with HAp/PLGA was coupled to the 
exposure to Pb and Cd, the treatment was detrimental to the 
healed bone and to the remote organs in the experimental animals. 
Comparing the outcomes of the treatment 6 and 12 weeks after the 
implantation at the same concentration of Pb and Cd, a significantly lower 
bone mass and the quality of the reconstructed bone can be deduced 
from the lower Ca content in bone at longer post-implantation times (12 
weeks < 6 weeks) and also at higher heavy ion doses (A3 < A2) in Pb- and 
Cd-containing HAp/PLGA sample groups, A2 and A3 (Fig. 2). A more 
pronounced difference in the bone mass between the control and the 
experimental groups observed 12 weeks after the implantation than 6 
weeks after it was due to the time-dependent accumulation of Pb and Cd 
in tissues. These metals tend to accumulate in calcified tissues
64,65
 and this 
accumulation coincides with the reduction in the concentration of Ca in 
bone, which, in turn, leads to a reduction in the mechanical resilience of 
the bone. Cd, for example, induces bone loss and creates osteoporotic 
symptoms in bone following environmental levels of exposure
66
, while Pb 
equally reduces the bone Ca content
67
, similar to the effects observed in 
this study (Fig. 2). Human populations thriving on land polluted with 
unsafe levels of Cd are known to be at a higher risk for bone fracture
68,69
 
but also renal dysfunction.
70
 Prolonged exposure to low levels of Cd is 
known to cause histological changes in certain parenchymatous organs, 
especially kidneys, liver, lungs, nasal mucosa, etc.
71,72
 and is in agreement 
with the similar histopathological changes observed in kidneys and liver of 
animals challenged here with Cd and Pb. These metals are extremely 
motile and easily distributable to remote tissues through the 
bloodstream.
73,74
 As demonstrated by this study, their effects on organs 
distant from the region of bone subjected to the surgical treatment are 
pronounced. 
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Conclusions 
Here we report on the simultaneous evaluation of the effect of a 
hybrid biomaterial systems composed of HAp nanoparticles coated 
by the bioresorbable polymer, PLGA, on the quality of bone tissue 
reconstruction and the quality of tissues and organs potentially 
influenced by the degradation products generated during and after 
the reconstruction. The obtained results show that the implantation of 
HAp/PLGA particles into the alveolar bone of experimental animals 
increases the mass of Ca in bones, without pathological changes in the 
liver and the kidneys. This effect is more pronounced after longer 
periods of time following the implantation of the nanoparticles. Both low 
and high concentrations of Pb and Cd added to HAp/PLGA nanoparticles 
decrease their regenerative impact, whereas the effect of the higher 
concentrations of these toxic elements is more pronounced than that of 
the lower ones. This can be explained by the tendency of the heavy 
metals to deposit in calcified tissues, where their concentration rises over 
time, causing the reduction in the concentration of Ca, along with the 
mechanical weakening of jawbones. The transport of Pb and Cd from the 
implantation site to distant tissues and organs, such as liver and kidneys, 
via bodily fluids caused a severe irreversible damage to these 
parenchymatous organs. The cumulative effect of Pb and Cd, particularly 
apparent 12 weeks after the implantation, induced significant 
histopathological changes to the mentioned organs, including severe 
stasis. Apart from it, degeneration and necrosis of the tubular epithelium 
was also noticed. Glomeruli displayed morphological changes caused by 
the stasis, such as the dilatation of capillary lumens, erythrocyte overflow 
and thrombosis in numerous capillaries. Some of the blood vessels were 
affected by parietal thrombosis too. Hepatocytes, in turn, exhibited 
severe vacuolar, hydropic, degenerative and necrotic changes, with a 
drastic destruction of liver plates accompanied by prominent venostasis. 
These results suggest that exposures to heavy metals as environmental or 
procedural contaminants should be carefully monitored, for their effect 
on the success of an otherwise immaculate therapy can be immense. 
Synergies of this type, involving the combination of a tissue 
regeneration approach and exposure to an adverse environmental 
chemical, should be paid close attention to in the process of 
designing appropriate reconstructive therapies. 
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